EPISODE · Oct 7, 2025 · 28 MIN
Ep. 19 - FDA Warnings, Compounded GLP1s, and the Next Generation of Weight Loss Medications
from The Scalpel's Edge · host Dr. Tim Sayed
In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes a deep dive into the shifting regulatory landscape for compounded GLP1 medications and what recent FDA warning letters mean for providers, pharmacies, and patients. He also reviews promising new clinical trial data on Pfizer’s experimental drug MET97, which may offer greater weight loss with fewer side effects compared to current options. From the nuances of verbiage in compounding claims to the future of monthly dosing and oral formulations, this conversation explores where the science and safety of GLP1 treatments are headed.Contact Dr. Tim Sayed:Phone: (858) 247-2933Email: [email protected]: timsayedmd.comInstagram: @timsayedmdYouTube: @TimsayedmdFacebook: Tim Sayed MD
Embed this episode
What this episode covers
In this episode of The Scalpel’s Edge, Dr. Tim Sayed takes a deep dive into the shifting regulatory landscape for compounded GLP1 medications and what recent FDA warning letters mean for providers, pharmacies, and patients. He also reviews promising new clinical trial data on Pfizer’s experimental drug MET97, which may offer greater weight loss with fewer side effects compared to current options. From the nuances of verbiage in compounding claims to the future of monthly dosing and oral formu...
NOW PLAYING
Ep. 19 - FDA Warnings, Compounded GLP1s, and the Next Generation of Weight Loss Medications
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.